Morgan Stanley initiated coverage of enGene with an Overweight rating and $40 price target. The analyst says the company’s Phase 1 data for EG-70 in bladder cancer have been encouraging, suggesting it could provide comparable efficacy as other candidates in development. The firm notes the company has multiple readouts expected in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ENGN: